Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Overview

This Phase I clinical trial evaluates the safety, tolerability, and diagnostic performance of a novel PET imaging agent, [18F]NOTA-ABY030, in patients with head and neck squamous cell carcinoma (HNSCC) who present with indeterminate lesions on standard imaging. The investigational agent is a radiolabeled anti-EGFR affibody designed to improve tumor specificity and reduce background signal, potentially enhancing diagnostic accuracy.

Drug / Compound